http://120.24.161.253:5617/index.php?action=history&feed=atom&title=%E4%B9%B3%E8%85%BA%E7%99%8C-%E4%B8%B4%E5%BA%8A%E8%A1%A8%E7%8E%B0-HER-2%E9%98%B3%E6%80%A7 2026-05-09T01:50:29Z 本wiki的该页面的版本历史 MediaWiki 1.30.0 http://120.24.161.253:5617/index.php?title=%E4%B9%B3%E8%85%BA%E7%99%8C-%E4%B8%B4%E5%BA%8A%E8%A1%A8%E7%8E%B0-HER-2%E9%98%B3%E6%80%A7&diff=1578452&oldid=prev 2024-07-06T14:00:00Z

<p>修改1</p> <table class="diff diff-contentalign-left" data-mw="interface"> <tr style="vertical-align: top;" lang="zh-CN"> <td colspan="1" style="background-color: white; color:black; text-align: center;">←上一版本</td> <td colspan="1" style="background-color: white; color:black; text-align: center;">2024年7月6日 (六) 14:00的版本</td> </tr><tr><td colspan="2" style="text-align: center;" lang="zh-CN"><div class="mw-diff-empty">（没有差异）</div> </td></tr></table>

Admin http://120.24.161.253:5617/index.php?title=%E4%B9%B3%E8%85%BA%E7%99%8C-%E4%B8%B4%E5%BA%8A%E8%A1%A8%E7%8E%B0-HER-2%E9%98%B3%E6%80%A7&diff=1578453&oldid=prev 2024-07-06T12:20:36Z

<p>导入1个版本</p> <table class="diff diff-contentalign-left" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr style="vertical-align: top;" lang="zh-CN"> <td colspan="2" style="background-color: white; color:black; text-align: center;">←上一版本</td> <td colspan="2" style="background-color: white; color:black; text-align: center;">2024年7月6日 (六) 12:20的版本</td> </tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l11" >第11行：</td> <td colspan="2" class="diff-lineno">第11行：</td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>===乳腺癌超声征象与肿瘤分子生物学指标雌激素受体(ER)、孕激素受体(PR)、HER-2之间的相关性（中华医学会文献）===</div></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>===乳腺癌超声征象与肿瘤分子生物学指标雌激素受体(ER)、孕激素受体(PR)、HER-2之间的相关性（中华医学会文献）===</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>结果:50例[[乳腺癌]]患者中,34例ER阳性,占68.0%,35例PR阳性,占70.0%,12例[[HER-2阳性]],占24.0%.</div></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>结果:50例[[乳腺癌]]患者中,34例ER阳性,占68.0%,35例PR阳性,占70.0%,12例[[HER-2阳性]],占24.0%.</div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">===基于DCE-MRI瘤内及瘤周影像组学联合TIC分型及Ki-67预测乳腺癌患者HER-2表达（中华医学会文献）===</ins></div></td></tr> <tr><td colspan="2">&#160;</td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;">材料与方法 回顾性收集2018年6月至2022年9月经病理证实为[[乳腺癌]]的患者病例资料272例，其中[[HER-2阳性]]139例，阴性133例，所有病例均在治疗前进行DCE-MRI检查。</ins></div></td></tr> </table>

KGadmin http://120.24.161.253:5617/index.php?title=%E4%B9%B3%E8%85%BA%E7%99%8C-%E4%B8%B4%E5%BA%8A%E8%A1%A8%E7%8E%B0-HER-2%E9%98%B3%E6%80%A7&diff=615702&oldid=prev 2021-11-22T13:33:08Z

<p>导入1个版本</p> <table class="diff diff-contentalign-left" data-mw="interface"> <tr style="vertical-align: top;" lang="zh-CN"> <td colspan="1" style="background-color: white; color:black; text-align: center;">←上一版本</td> <td colspan="1" style="background-color: white; color:black; text-align: center;">2021年11月22日 (一) 13:33的版本</td> </tr><tr><td colspan="2" style="text-align: center;" lang="zh-CN"><div class="mw-diff-empty">（没有差异）</div> </td></tr></table>

Admin http://120.24.161.253:5617/index.php?title=%E4%B9%B3%E8%85%BA%E7%99%8C-%E4%B8%B4%E5%BA%8A%E8%A1%A8%E7%8E%B0-HER-2%E9%98%B3%E6%80%A7&diff=615697&oldid=prev 2021-10-19T13:56:59Z

<p>修改1</p> <p><b>新页面</b></p><div>主实体：[[乳腺癌]]，关系：[[临床表现]] ，尾实体：[[HER-2阳性]]<br /> <br /> 实体ID:''6656478''<br /> ==关系介绍==<br /> 待补充<br /> <br /> ==来源==<br /> ===Survivin和Caspase-9基因在新疆维族、汉族HER-2阳性乳腺癌组织中的表达及意义（中华医学会文献）===<br /> 方法:选取初次确诊为[[乳腺癌]]的女性患者,经术前或者术后免疫组化检查为[[HER-2阳性]]者共48例,以各民族良性乳腺病患者标本为对照.<br /> <br /> ===乳腺癌超声征象与肿瘤分子生物学指标雌激素受体(ER)、孕激素受体(PR)、HER-2之间的相关性（中华医学会文献）===<br /> 结果:50例[[乳腺癌]]患者中,34例ER阳性,占68.0%,35例PR阳性,占70.0%,12例[[HER-2阳性]],占24.0%.</div>

Admin